Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals
Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This study aims to determine whether people living with HIV (PLHIV) with suboptimal medical adherence can achieve better viral suppression with long-acting antiretrovirals (LA) compared to all-oral antiretrovirals.
Phase:
PHASE3
Details
Lead Sponsor:
Chang Gung Memorial Hospital
Collaborator:
Taoyuan General Hospital
Treatments:
cabotegravir cabotegravir, rilpivirine drug combination Rilpivirine